6:04 PM
 | 
Apr 25, 2013
 |  BC Extra  |  Financial News

Celgene submits apremilast NDA, reports earns

Celgene Corp. (NASDAQ:CELG) disclosed in its 1Q13 earnings that it submitted an NDA to FDA in March for apremilast to treat active psoriatic arthritis. Next half, the biotech plans to submit an sNDA to FDA for the oral phosphodiesterase-4 (PDE-4) inhibitor for moderate-to-severe plaque psoriasis, and a combined...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >